NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026.

Dr. Lior Shaltiel, PhD, Chief Executive Officer of NurExone, commented, “Engaging with scientific, industry, and investor audiences is a core part of our strategy, and March includes two important forums. For NurExone, NANO.IL.2026 and Advanced Therapies represent two sides of the same innovation pathway - one focused on nano scale biology and delivery technologies, and the other on what it takes to translate them into a therapy built for consistent manufacturing, regulatory and clinical progress.”

NurExone will participate in NANO.IL.2026, an international nanoscience and nanotechnology conference and exhibition taking place in Jerusalem from March 8 to 10, 2026. Dr. Shaltiel will serve as an invited speaker in the Nano Biotech Industrial Approach track and as a co-chair of Nano Biotech Industrial Approach Part B. Exosomes size is at the nano scale, and NurExone’s platform is designed to develop them into minimally invasive regenerative therapies focused on central nervous system injuries.

In addition, Dr. Shaltiel will be speaking at the Advanced Therapies Congress in London in March 2026, Europe’s largest commercial cell and gene therapy conference and exhibition. The congress brings together global leaders in advanced therapeutics to address clinical translation, manufacturing scalability, commercialization, and investment trends.

Corporate Update

The Company announced that Mr. Jacob Licht will be stepping down from his roles as Chief Executive Officer of Exo-Top Inc. and Vice President, Corporate Development at NurExone at the end of March 2026 for personal reasons. The Company thanks Mr. Licht for his contributions and dedication and wishes him continued success. The Company’s management team will assume his responsibilities until further notice.

About NurExone

NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

Russo Partners LLC
Investor Relations – United States
215 Park Ave S, Suite 1905
New York, NY 10003
Phone: 212-845-4200

FORWARD-LOOKING STATEMENTS

This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company’s anticipated participation in the conferences in March 2026; Dr. Shaltiel’s speaking at the conferences and participation in the panel discussions; the expected timing of Mr. Jacob Licht’s departure and the transition of his responsibilities; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the referenced conferences will proceed as scheduled; speaking engagements and participation will occur as currently planned; Mr. Licht’s transition and departure will occur on the expected timeline; the Company will be able to maintain continuity of its corporate development and subsidiary leadership functions through interim measures and/or additional personnel as required; that there will be no events or circumstances outside of the Company’s reasonable control that materially impact the foregoing; and the NurExone platform technology has the ability to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: changes to conference scheduling or programming; the availability of management and personnel; the risk that transitions in senior personnel take longer than anticipated or create operational disruption; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.